Anti-angiogenic Barriers to Tumor Development View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

1994-2012

FUNDING AMOUNT

2608105 USD

ABSTRACT

DESCRIPTION (provided by applicant): Pigment epithelium-derived factor (PEDF) is a 50 kD secreted glycoprotein made by many cell types. It has been shown to be a potent inhibitor of pathologic angiogenesis by inducing endothelial cell apoptosis. We developed a mouse null for PEDF that spontaneously remodels the liver matrix, accumulates lipid, and demonstrates progressive fibrosis with increased vascularity. All animals develop dysplastic lesions or hepatocellular carcinoma (HCC). These changes were associated with activated hepatic stellate cells and increased levels of angiogenic inducers, VEGF, and leptin in the PEDF null liver. Moreover, a significant decrease in PEDF mRNA was evident when PPAR gamma was over-expressed in rodent livers and PEDF interacted with nuclear receptors suggesting that PEDF may be a new target gene for a hormone receptor family known to be important regulators of lipid metabolism. Preliminary testing of PEDF gene therapy in a xenograft rodent model appeared promising when hepatoma tumors were found to have markedly reduced levels of VEGF and increased tumor necrosis. These results led us to the hypothesis that loss of multifunctional PEDF in the liver triggers an imbalance in hepatocyte and stellate cell-derived extracellular factors, thus, promoting a highly angiogenic environment capable of supporting the growth of tumors. Using cultured hepatocytes, stellate cells and the PEDF null mouse model, we will explore changes in angiogenic activity, epithelial growth, and elucidate mechanisms by which tumor cells down-regulate PEDF. PEDF null mice will be crossed with leptin-deficient mice to better characterize the signaling pathways between PEDF, leptin, and VEGF. PEDF expression levels will be examined in human HCC to assess its utility as a tumor prognostic marker. Xenograft models of HCC will be treated with recombinant PEDF protein or with PEDF gene therapy to characterize the actions of PEDF on tumor growth. The interaction of PEDF and PPARgamma will be investigated by evaluating the functional activity of PPAR response elements in the PEDF gene and the nuclear signaling pathways explored. This proposed study has the potential to identify a novel signaling pathway in the pathogenesis of liver disease and it may validate PEDF gene therapy as a potent new agent to combat liver cancer. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=7924504

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "2608105"
    }, 
    "description": "DESCRIPTION (provided by applicant): Pigment epithelium-derived factor (PEDF) is a 50 kD secreted glycoprotein made by many cell types. It has been shown to be a potent inhibitor of pathologic angiogenesis by inducing endothelial cell apoptosis. We developed a mouse null for PEDF that spontaneously remodels the liver matrix, accumulates lipid, and demonstrates progressive fibrosis with increased vascularity. All animals develop dysplastic lesions or hepatocellular carcinoma (HCC). These changes were associated with activated hepatic stellate cells and increased levels of angiogenic inducers, VEGF, and leptin in the PEDF null liver. Moreover, a significant decrease in PEDF mRNA was evident when PPAR gamma was over-expressed in rodent livers and PEDF interacted with nuclear receptors suggesting that PEDF may be a new target gene for a hormone receptor family known to be important regulators of lipid metabolism. Preliminary testing of PEDF gene therapy in a xenograft rodent model appeared promising when hepatoma tumors were found to have markedly reduced levels of VEGF and increased tumor necrosis. These results led us to the hypothesis that loss of multifunctional PEDF in the liver triggers an imbalance in hepatocyte and stellate cell-derived extracellular factors, thus, promoting a highly angiogenic environment capable of supporting the growth of tumors. Using cultured hepatocytes, stellate cells and the PEDF null mouse model, we will explore changes in angiogenic activity, epithelial growth, and elucidate mechanisms by which tumor cells down-regulate PEDF. PEDF null mice will be crossed with leptin-deficient mice to better characterize the signaling pathways between PEDF, leptin, and VEGF. PEDF expression levels will be examined in human HCC to assess its utility as a tumor prognostic marker. Xenograft models of HCC will be treated with recombinant PEDF protein or with PEDF gene therapy to characterize the actions of PEDF on tumor growth. The interaction of PEDF and PPARgamma will be investigated by evaluating the functional activity of PPAR response elements in the PEDF gene and the nuclear signaling pathways explored. This proposed study has the potential to identify a novel signaling pathway in the pathogenesis of liver disease and it may validate PEDF gene therapy as a potent new agent to combat liver cancer.", 
    "endDate": "2012-07-31T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.48336.3a", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2472040", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2472040"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "R01CA064239"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "endothelial cell apoptosis", 
      "hepatic stellate cells", 
      "pathway", 
      "tumor", 
      "hypothesis", 
      "tumor growth", 
      "proposed study", 
      "leptin", 
      "prognostic marker", 
      "PEDF null mice", 
      "mouse null", 
      "rodent liver", 
      "multifunctional PEDF", 
      "nuclear receptors", 
      "factors", 
      "loss", 
      "hepatocytes", 
      "description", 
      "pathologic angiogenesis", 
      "growth", 
      "applicants", 
      "PPARgamma", 
      "human HCC", 
      "liver disease", 
      "extracellular factors", 
      "potent new agents", 
      "recombinant PEDF protein", 
      "mechanism", 
      "progressive fibrosis", 
      "leptin-deficient mice", 
      "dysplastic lesions", 
      "pathogenesis", 
      "PEDF gene", 
      "Kd", 
      "pigment epithelium", 
      "functional activity", 
      "PEDF expression levels", 
      "glycoprotein", 
      "stellate cells", 
      "epithelial growth", 
      "lipid metabolism", 
      "important regulator", 
      "preliminary testing", 
      "PEDF null mouse model", 
      "VEGF", 
      "many cell types", 
      "xenograft model", 
      "PEDF null liver", 
      "hepatoma tumor", 
      "tumor necrosis", 
      "action", 
      "utility", 
      "PEDF mRNA", 
      "angiogenic inducer", 
      "liver", 
      "PEDF", 
      "cultured hepatocytes", 
      "imbalance", 
      "liver matrix", 
      "interaction", 
      "PPAR gamma", 
      "levels", 
      "animals", 
      "liver cancer", 
      "tumor cells", 
      "hepatocellular carcinoma", 
      "xenograft rodent models", 
      "new target genes", 
      "vascularity", 
      "hormone receptor family", 
      "novel", 
      "changes", 
      "PEDF gene therapy", 
      "angiogenic activity", 
      "PPAR response element", 
      "potent inhibitor", 
      "tumor development", 
      "nuclear signalling pathways", 
      "Anti-angiogenic Barriers", 
      "results", 
      "significant decrease", 
      "angiogenic environment"
    ], 
    "name": "Anti-angiogenic Barriers to Tumor Development", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.240372.0", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.240372.0", 
          "name": "NORTHSHORE UNIVERSITY HEALTHSYSTEM", 
          "type": "Organization"
        }, 
        "familyName": "CRAWFORD", 
        "givenName": "SUSAN E.", 
        "id": "sg:person.0625654477.36", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.0625654477.36", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2472040"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T12:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_6.xml.gz", 
    "startDate": "1994-07-01T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=7924504"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2472040'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2472040'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2472040'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2472040'


 

This table displays all metadata directly associated to this object as RDF triples.

126 TRIPLES      19 PREDICATES      104 URIs      96 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2472040 schema:about anzsrc-for:2211
2 schema:amount N90cec05108744956adbffc5c9a7c6197
3 schema:description DESCRIPTION (provided by applicant): Pigment epithelium-derived factor (PEDF) is a 50 kD secreted glycoprotein made by many cell types. It has been shown to be a potent inhibitor of pathologic angiogenesis by inducing endothelial cell apoptosis. We developed a mouse null for PEDF that spontaneously remodels the liver matrix, accumulates lipid, and demonstrates progressive fibrosis with increased vascularity. All animals develop dysplastic lesions or hepatocellular carcinoma (HCC). These changes were associated with activated hepatic stellate cells and increased levels of angiogenic inducers, VEGF, and leptin in the PEDF null liver. Moreover, a significant decrease in PEDF mRNA was evident when PPAR gamma was over-expressed in rodent livers and PEDF interacted with nuclear receptors suggesting that PEDF may be a new target gene for a hormone receptor family known to be important regulators of lipid metabolism. Preliminary testing of PEDF gene therapy in a xenograft rodent model appeared promising when hepatoma tumors were found to have markedly reduced levels of VEGF and increased tumor necrosis. These results led us to the hypothesis that loss of multifunctional PEDF in the liver triggers an imbalance in hepatocyte and stellate cell-derived extracellular factors, thus, promoting a highly angiogenic environment capable of supporting the growth of tumors. Using cultured hepatocytes, stellate cells and the PEDF null mouse model, we will explore changes in angiogenic activity, epithelial growth, and elucidate mechanisms by which tumor cells down-regulate PEDF. PEDF null mice will be crossed with leptin-deficient mice to better characterize the signaling pathways between PEDF, leptin, and VEGF. PEDF expression levels will be examined in human HCC to assess its utility as a tumor prognostic marker. Xenograft models of HCC will be treated with recombinant PEDF protein or with PEDF gene therapy to characterize the actions of PEDF on tumor growth. The interaction of PEDF and PPARgamma will be investigated by evaluating the functional activity of PPAR response elements in the PEDF gene and the nuclear signaling pathways explored. This proposed study has the potential to identify a novel signaling pathway in the pathogenesis of liver disease and it may validate PEDF gene therapy as a potent new agent to combat liver cancer.
4 schema:endDate 2012-07-31T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.48336.3a
6 schema:identifier N61bf14eb6dbf4c9594094b31ace822db
7 Nbf3a9751c93d4ee7ad9be881cc6dd28f
8 schema:inLanguage en
9 schema:keywords Anti-angiogenic Barriers
10 Kd
11 PEDF
12 PEDF expression levels
13 PEDF gene
14 PEDF gene therapy
15 PEDF mRNA
16 PEDF null liver
17 PEDF null mice
18 PEDF null mouse model
19 PPAR gamma
20 PPAR response element
21 PPARgamma
22 VEGF
23 action
24 angiogenic activity
25 angiogenic environment
26 angiogenic inducer
27 animals
28 applicants
29 changes
30 cultured hepatocytes
31 description
32 dysplastic lesions
33 endothelial cell apoptosis
34 epithelial growth
35 extracellular factors
36 factors
37 functional activity
38 glycoprotein
39 growth
40 hepatic stellate cells
41 hepatocellular carcinoma
42 hepatocytes
43 hepatoma tumor
44 hormone receptor family
45 human HCC
46 hypothesis
47 imbalance
48 important regulator
49 interaction
50 leptin
51 leptin-deficient mice
52 levels
53 lipid metabolism
54 liver
55 liver cancer
56 liver disease
57 liver matrix
58 loss
59 many cell types
60 mechanism
61 mouse null
62 multifunctional PEDF
63 new target genes
64 novel
65 nuclear receptors
66 nuclear signalling pathways
67 pathogenesis
68 pathologic angiogenesis
69 pathway
70 pigment epithelium
71 potent inhibitor
72 potent new agents
73 preliminary testing
74 prognostic marker
75 progressive fibrosis
76 proposed study
77 recombinant PEDF protein
78 results
79 rodent liver
80 significant decrease
81 stellate cells
82 tumor
83 tumor cells
84 tumor development
85 tumor growth
86 tumor necrosis
87 utility
88 vascularity
89 xenograft model
90 xenograft rodent models
91 schema:name Anti-angiogenic Barriers to Tumor Development
92 schema:recipient N7f8b86ce227c4851bd178a74ba27076d
93 sg:person.0625654477.36
94 https://www.grid.ac/institutes/grid.240372.0
95 schema:sameAs https://app.dimensions.ai/details/grant/grant.2472040
96 schema:sdDatePublished 2019-03-07T12:13
97 schema:sdLicense https://scigraph.springernature.com/explorer/license/
98 schema:sdPublisher N5e92cb2129ec433399557809ee1429ea
99 schema:startDate 1994-07-01T00:00:00Z
100 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=7924504
101 sgo:license sg:explorer/license/
102 sgo:sdDataset grants
103 rdf:type schema:MonetaryGrant
104 N5e92cb2129ec433399557809ee1429ea schema:name Springer Nature - SN SciGraph project
105 rdf:type schema:Organization
106 N61bf14eb6dbf4c9594094b31ace822db schema:name nih_id
107 schema:value R01CA064239
108 rdf:type schema:PropertyValue
109 N7f8b86ce227c4851bd178a74ba27076d schema:member sg:person.0625654477.36
110 schema:roleName PI
111 rdf:type schema:Role
112 N90cec05108744956adbffc5c9a7c6197 schema:currency USD
113 schema:value 2608105
114 rdf:type schema:MonetaryAmount
115 Nbf3a9751c93d4ee7ad9be881cc6dd28f schema:name dimensions_id
116 schema:value 2472040
117 rdf:type schema:PropertyValue
118 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
119 rdf:type schema:DefinedTerm
120 sg:person.0625654477.36 schema:affiliation https://www.grid.ac/institutes/grid.240372.0
121 schema:familyName CRAWFORD
122 schema:givenName SUSAN E.
123 rdf:type schema:Person
124 https://www.grid.ac/institutes/grid.240372.0 schema:name NORTHSHORE UNIVERSITY HEALTHSYSTEM
125 rdf:type schema:Organization
126 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...